Six firms are set to join the Nasdaq 100 Index as part of its annual reconstitution, the benchmark’s overseer said Friday.

Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...

Leerink analyst Mani Foroohar lowered the firm’s price target on Alnylam to $351 from $370 and keeps a Market Perform rating on the shares. Heading into 2026, the firm is refreshing its TTR market ...

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...

Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others ...

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to market ...

The latest update on Tuesday morning shows Alnylam Pharmaceuticals shares up by 3.84%, trading at $472.0. At this price, ...

The burgeoning field of transthyretin amyloid cardiomyopathy (ATTR-CM), which spurred excitement over a potential $20 billion ...

An Alnylam Pharmaceuticals drug that treats nerve pain caused by an inherited protein disorder now has results from a pivotal clinical trial showing the drug also helps patients suffering the ...

Alnylam must wait a few months longer for a verdict on its potential blockbuster-in-waiting vutrisiran. The U.S. FDA has slapped a three-month delay on its review of the RNA interference (RNAi) ...

FDA has put Alnylam’s RNAi treatment for the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis on its regulatory fast track. Alnylam secured the designation for the candidate, ...

The age of RNA interference drugs has arrived. Alnylam Pharmaceuticals announced positive results Wednesday from a closely watched phase 3 clinical trial of patisiran, the company’s lead drug designed ...